Haleon Doubles Down on China with £65M Oral Health Manufacturing Hub — Haleon plc

Event summary

Haleon investing £65M in new Shanghai oral health manufacturing site to expand into China’s tier 2 and 3 cities.
parodontax brand adapted for Chinese consumers with sweeter, more fragrant notes while maintaining clinical efficacy.
Company aims to extend parodontax distribution to 30 cities by end of 2027, reaching over 250 million people.
Haleon completed full acquisition of TSKF joint venture in June 2025 for approximately £700M.

The big picture

Haleon’s investments underscore its long-term confidence in China’s consumer healthcare market, particularly as rising incomes and health awareness drive demand for premium, science-backed oral care products. The company is positioning itself to capture growth in a category where over 70% of Chinese adults experience gum issues, with the world’s largest gum health market valued at approximately £860 million.

What we're watching

Market Penetration: Whether Haleon can successfully adapt its premium oral care products to compete with local flavor preferences in China’s rapidly growing tier 2 and 3 cities.
Supply Chain Efficiency: The pace at which Haleon realizes £800M in gross productivity savings through its new Shanghai manufacturing facility and TSKF acquisition.
Competitive Positioning: How Haleon’s multi-channel retail strategy will affect its market share against established local and international oral care brands in China.